Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications.
Until now there are few controlled studies that have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome.
But in this study, which was published on March 17,2018 in the Lancet Jurnals, the reserchers assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients.
The study...
In 24 clinical sites in the USA, the Netherlands, and Poland, reserchers investigated the efficacy of cannabidiol as add-on therapy for drop seizures in patients with treatment-resistant Lennox-Gastaut syndrome.All patients had Lennox-Gastaut syndrome, including a history of slow spike-and-wave patterns on electroencephalogram, evidence of more than one type of generalised seizure for at least 6 months, at least two drop seizures per week during the 4-week baseline period, and had not responded to treatment with at least two antiepileptic drugs.
Until now there are few controlled studies that have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome.
But in this study, which was published on March 17,2018 in the Lancet Jurnals, the reserchers assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients.
The study...
In 24 clinical sites in the USA, the Netherlands, and Poland, reserchers investigated the efficacy of cannabidiol as add-on therapy for drop seizures in patients with treatment-resistant Lennox-Gastaut syndrome.All patients had Lennox-Gastaut syndrome, including a history of slow spike-and-wave patterns on electroencephalogram, evidence of more than one type of generalised seizure for at least 6 months, at least two drop seizures per week during the 4-week baseline period, and had not responded to treatment with at least two antiepileptic drugs.